摘要:目的 探討替吉奧聯(lián)合奧沙利鉑治療晚期胃癌的近期療效以及護(hù)理干預(yù)對治療順利進(jìn)行的作用。方法 入組28例經(jīng)病理學(xué)確診的晚期胃癌患者,均接受替吉奧聯(lián)合奧沙利鉑治療,觀察其近期療效及毒副反應(yīng),并針對常見毒副反應(yīng)給出相應(yīng)的護(hù)理干預(yù),總結(jié)護(hù)理經(jīng)驗(yàn)。結(jié)果 全組28例晚期胃癌患者中,CR 1例,PR 14例,SD 8例,PD 5例,總有效率為53.57%,主要毒副反應(yīng)包括周圍神經(jīng)毒性、骨髓抑制、胃腸道反應(yīng)、口腔黏膜炎、靜脈炎及皮疹等,但大多為輕度,經(jīng)對癥處理后均可緩解。結(jié)論 在精心護(hù)理干預(yù)的情況下,采取替吉奧聯(lián)合奧沙利鉑方案治療晚期胃癌安全有效。
關(guān)鍵詞:晚期胃癌;替吉奧;奧沙利鉑;護(hù)理
Observation of Efficacy and Nursing S-1 Combined with Oxaliplatin for Patients with Advanced Gastric Cancer
XU Ke-pu,XIAO Xue-qing,XU Li-Juan
(Department of Oncology,The 152nd Hospital of PLA,Pingdingshan 467000,Henan,China)
Abstract:Objective To investigate the short-term efficacy and nursing interventions of S-1 combined with oxaliplatin for patients with advanced gastric cancer. Methods 28 patients with advanced gastric cancer underwent S-1 combined with oxaliplatin, the efficacy and toxicities were observed, and the corresponding nursing interventions for common toxicities were recorded. Results All the 28 patients with advanced gastric cancer, CR was observed in the 1 case, PR in the 14 cases, SD in the 8 cases, PD in the 5 cases, the total effective rate was 53.57%, the main toxicities were peripheral neurotoxicity, bone marrow suppression, gastrointestinal reactions, oral mucositis, phlebitis and rash, but were mostly mild, and could be alleviated after symptomatic treatment. Conclusion After intensive care intervention, S-1 combined with oxaliplatin is safe and effective for the patients with advanced gastric cancer.
Key words:Advanced gastric cancer; S-1; Oxaliplatin; Nursing
胃癌是常見的人類惡性腫瘤之一,發(fā)病率和死亡率均居惡性腫瘤前列,嚴(yán)重影響了人們生命健康。替吉奧是一種口服類氟尿嘧啶衍生物,用于臨床,其療效已得到證實(shí),且相較于氟尿嘧啶,毒副反應(yīng)更輕。奧沙利鉑是第3代鉑類抗腫瘤藥物,對胃腸道惡性腫瘤具有較好療效,且與氟尿嘧啶聯(lián)用是胃癌等的常用聯(lián)合方案,已被證實(shí)切實(shí)可行。作者為了進(jìn)一步降低聯(lián)合方案的毒副反應(yīng),用替吉奧代替氟尿嘧啶與奧沙利鉑聯(lián)合用于晚期胃癌的治療,并在治療過程中及治療后采取個(gè)體化的精心護(hù)理干預(yù),以期使化療順利進(jìn)行,并將毒副反應(yīng)發(fā)生率和發(fā)生程度降到最低。
1 資料與方法
1.1一般資料 選擇2010年1月~2013年12月于解放軍152醫(yī)院腫瘤科住院治療的晚期胃癌患者28例,男16例,女12例;……